"Triazoles" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
No definition found.
Descriptor ID |
D014230
|
MeSH Number(s) |
D03.383.129.799
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Triazoles".
Below are MeSH descriptors whose meaning is more specific than "Triazoles".
This graph shows the total number of publications written about "Triazoles" by people in this website by year, and whether "Triazoles" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1994 | 2 | 0 | 2 |
1995 | 1 | 1 | 2 |
1996 | 1 | 2 | 3 |
1997 | 2 | 3 | 5 |
1998 | 4 | 0 | 4 |
1999 | 3 | 0 | 3 |
2000 | 4 | 2 | 6 |
2001 | 6 | 2 | 8 |
2002 | 9 | 0 | 9 |
2003 | 14 | 10 | 24 |
2004 | 13 | 5 | 18 |
2005 | 15 | 3 | 18 |
2006 | 14 | 3 | 17 |
2007 | 4 | 3 | 7 |
2008 | 9 | 3 | 12 |
2009 | 8 | 3 | 11 |
2010 | 9 | 7 | 16 |
2011 | 12 | 6 | 18 |
2012 | 13 | 7 | 20 |
2013 | 10 | 7 | 17 |
2014 | 7 | 11 | 18 |
2015 | 16 | 8 | 24 |
2016 | 8 | 7 | 15 |
2017 | 13 | 7 | 20 |
2018 | 6 | 8 | 14 |
2019 | 8 | 1 | 9 |
2020 | 7 | 3 | 10 |
2021 | 6 | 9 | 15 |
2022 | 1 | 2 | 3 |
2024 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Triazoles" by people in Profiles.
-
Endocrine-Sensitive Disease Rate in Postmenopausal Patients With Estrogen Receptor-Rich/ERBB2-Negative Breast Cancer Receiving Neoadjuvant Anastrozole, Fulvestrant, or Their Combination: A Phase 3 Randomized Clinical Trial. JAMA Oncol. 2024 Mar 01; 10(3):362-371.
-
Invasive fusariosis in patients with leukaemia in the era of mould-active azoles: increasing incidence, frequent breakthrough infections and lack of improved outcomes. J Antimicrob Chemother. 2024 Feb 01; 79(2):297-306.
-
Comparison of Mold Active Triazoles as Primary Antifungal Prophylaxis in Patients With Newly Diagnosed Acute Myeloid Leukemia in the Era of Molecularly Targeted Therapies. Clin Infect Dis. 2022 Oct 29; 75(9):1503-1510.
-
Triazole Priming as an Adaptive Response and Gateway to Resistance in Aspergillus fumigatus. Antimicrob Agents Chemother. 2022 08 16; 66(8):e0045822.
-
Selinexor in Advanced, Metastatic Dedifferentiated Liposarcoma: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial. J Clin Oncol. 2022 08 01; 40(22):2479-2490.
-
Systemic antifungal therapy with isavuconazonium sulfate or other agents in adults with invasive mucormycosis or invasive aspergillosis (non-fumigatus): A multicentre, non-interventional registry study. Mycoses. 2022 Feb; 65(2):186-198.
-
How different is invasive fusariosis in pediatric patients than in adults? A systematic review. Curr Opin Infect Dis. 2021 12 01; 34(6):619-626.
-
Rational Combination of CRM1 Inhibitor Selinexor and Olaparib Shows Synergy in Ovarian Cancer Cell Lines and Mouse Models. Mol Cancer Ther. 2021 12; 20(12):2352-2361.
-
Effect of High-Dose Posaconazole on Serum Levels in Adult Patients with Hematologic Malignancy. Antimicrob Agents Chemother. 2021 11 17; 65(12):e0123021.
-
Selinexor in combination with carboplatin and paclitaxel in patients with advanced solid tumors: Results of a single-center, multi-arm phase Ib study. Invest New Drugs. 2022 04; 40(2):290-299.